Taipei’s Bora Pharma Buys Stake in US CDMO

Bora Pharmaceuticals, a Taiwan CDMO, continued its acquisition of US-based CDMOs by acquiring a 30.5% share of San Diego’s Tanvex Biopharma. Bora will pay for the acquisition with new shares, though it didn’t release further details. The acquisition will extend Bora’s large-molecule CDMO services, adding 1,000-liter reactors to its own 500-liter devices. Bora also noted that the acquisition increases its US presence, preventing US government interference from the proposed US BIOSECURE Act, a cloud hanging over Chinese CDMOs that do business with US biopharmas. Bora will become Tanvex’s largest shareholder, and Bora Group Chairman Bobby Sheng will take over as Tanvex’s chairman in early 2025. More details....

Share this with colleagues: